Lexicon Pharmaceuticals Inc (LXRX) SEC 13F Holdings (Q2 2026) — Net Institutional Activity: $116.5M

LXRX ranks #3654 out of 37503 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

LXRX is a top-conviction position for Artal Group S.A. — at 45.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Artal Group S.A. has added to its LXRX position for two straight quarters, increasing it by $263.8M to reach $420.4M today.

Farther Finance Advisors, LLC has trimmed its LXRX position for two straight quarters, cutting it by $3.2K while still holding $5.0.

LXRX is down 2.7% today, but institutions show net buying of $116.5M this quarter — a divergence between today's price move and the underlying institutional flow.

LXRX reported a net loss of $61.1M over the trailing twelve months.

• Not yet profitable — net loss of $61.1M over the trailing twelve months
• Revenue declined 29.0% year over year
• Net income improved year over year, from -$120.6M to -$61.1M
• Operating cash flow was negative, using $67.9M in cash
• Current ratio of 4.88x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.72x equity — within a conventional range